Navigation Links
Pharmaxis in Medical News

Pharmaxis Announces NDA Filing for Aridol(TM) (Mannitol Bronchial Challenge Test)

.../ -- Pharmaxis, Inc., a wholly owned subsidiary of pharmaxis Ltd (ASX: PXS, Nasdaq: PXSL ), an emerging respi... Brett Charlton MBBS, PhD, Medical Director, pharmaxis Ltd, added, "Aridol is designed to measure bronchi... of elite athletes who are asthmatic. About pharmaxis ...

Pharmaxis to Expand Manufacturing Capacity

...nchitol to approximately 40,000 patients per year. pharmaxis is developing Bronchitol for the treatment of dise...pand initial capacity in a modular fashion. About pharmaxis pharmaxis (ACN 082 811 630) is a pharmaceutical company invo...
Pharmaxis in Medical Technology

ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia

SYDNEY, Australia, Sept. 30 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that a marketing application for the mucus clearing agent, Bronchitol, has been submitted to the Therapeutic Goods Administration (TGA) division of the Austral...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

...Newswire-Asia-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL ) is pleased to announce... averages 1-2% per year. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "We are delighted th...treating cystic fibrosis in Europe and elsewhere. pharmaxis will now move to file a marketing application late...

Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis

...le with cystic fibrosis. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "We are very pleased to announce this major milestone for pharmaxis and look forward to the results of the study with ... Bronchitol in people with cystic fibrosis. pharmaxis has received Orphan Drug Designation and fast trac...

Pharmaxis Announces New Drug Application Submission for Aridol(TM)

...Newswire-Asia-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS, Nasdaq: PXSL ) today announced it had... The NDA application is the vehicle through which pharmaxis formally proposes that the FDA approve a new pharm...es complete and ready to use. Alan Robertson, pharmaxis Chief Executive Officer said: "We are delighted to...

Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins

...ua-PRNewswire-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it h...chitol for cystic fibrosis in the United States. pharmaxis Chief Executive Officer Dr Alan Robertson said: "W...com.au/library/2008_09_04_CF302_Commences.pdf . pharmaxis is developing Bronchitol as a treatment to improve...

12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis

...ua-PRNewswire-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the ...es were a consequence of the underlying disease. pharmaxis CEO Alan Robertson said: "Pharmaxis intends to fil...rmaceutical markets suffer from bronchiectasis and pharmaxis expects Bronchitol to be the first targeted medica...

Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment

...baseline in FEV1 (forced expiratory volume in one second) after 26 weeks. pharmaxis Chief Executive Officer Alan Robertson said: "It is rewarding to reach this...esults helping to shape cystic fibrosis clinical practice in the future." pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Fo...

Bronchitol Cystic Fibrosis Dose Trial Results Positive

...re-FirstCall/ -- Speciality pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced results f...% on 240 mg, +1.5% on 120 mg and -0.6% on 40 mg. pharmaxis Chief Executive Officer Alan Robertson said, "The ...per year during their life, as measured by FEV1. pharmaxis has received Orphan Drug Designation and fast trac...

Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial

... and/or data analyses are acceptable to the FDA. pharmaxis previously agreed on the trial design with the Eur...f a successful shorter trial reported last year. pharmaxis CEO, Alan Robertson, said the company was pleased ...l trial is expected to soon close recruitment.'' pharmaxis is developing Bronchitol as a treatment to improve...

Pharmaxis Establishes Named Patient Program for Bronchitol

... The program will allow patients who are unable to participate in current pharmaxis clinical trials but who are considered by their physician to be suffering f... to medicines in countries where the product is yet to be authorised," said pharmaxis CEO Alan Robertson. "Bronchitol will be made available to people with a c...
Pharmaxis in Biological Technology

New Pharmaxis Board Appointment

SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors. Mr van den Broek is founder and managing partner of HSMR Advisor...

New Pharmaxis Board Appointment

SYDNEY, Australia, June 23 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors. Mr Delaat has 35 years experience in the global pharmaceutical industry, most re...

Pharmaxis Investor Conference Call

... SYDNEY, July 21 /PRNewswire-Asia/ -- pharmaxis Ltd (ASX: PXS) will release its June 2009 Quarterl...cording of the conference will be available on the pharmaxis website home page approximately 3 hours after the call. CONTACT: pharmaxis Investor Relations Tel: +61-2-9454-7200 ...

Pharmaxis to Voluntarily De-List from Nasdaq

... SYDNEY, July 12 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced a deci...t from the Nasdaq Global Market ("Nasdaq"). pharmaxis has recently completed a review of the demand from...itary Shares ("ADS's") on Nasdaq and the volume of pharmaxis ADS trading in the secondary Nasdaq market. The r...

Pharmaxis Closes Share Purchase Plan

... SYDNEY, June 29 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced it had raised A$7.2 million fro...ximately $7.2 million. Dr Alan Robertson, Chief Executive Officer of pharmaxis said, "We are very encouraged and appreciative of the level of support from...

Pharmaxis Announces Placement of $47 Million and Share Purchase Plan

... SYDNEY, June 3 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS, Nasdaq: PXSL ) today announced that i...acement strengthens the company's balance sheet as pharmaxis moves toward the European and U.S. commercial laun...its product Bronchitol for cystic fibrosis. pharmaxis will issue 20 million new fully paid ordinary shar...

U.S. FDA Accepts Aridol(TM) New Drug Application for Review

... SYDNEY, Australia, May 13 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced it had...e result of the review on 27 December 2009. pharmaxis is seeking approval for Aridol for "the assessment... test available in the U.S. Alan Robertson, pharmaxis Chief Executive Officer said: "We have been greatl...

Pharmaxis Investor Conference Call

... SYDNEY, Australia, April 6 /PRNewswire-Asia/ -- pharmaxis Ltd (AXS: PXS; Nasdaq: PXSL ) will release its M...cording of the conference will be available on the pharmaxis website home page approximately 3 hours after the call. CONTACT: pharmaxis Investor Relations Tel: +61-2-9454-7200 ...

Pharmaxis Appoints French Distributor for Aridol(TM)

... SYDNEY, March 11 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; NASDAQ: PXSL ) is pleased to announce that it has appointed Pr...after market the product to hospital specialists. Dr Alan Robertson, pharmaxis CEO said "We are delighted to announce this agreement and are looking forwa...

Pharmaxis Builds Senior Management Team

...cal Expert for Novartis. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "The appointment of ...ory and pharmacovigilance experience necessary for pharmaxis to bring Bronchitol successfully and rapidly to th...the company's head office in Sydney. About pharmaxis ...
Other Tags
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected as ... American Made Awards (MSAMAs), an annual competition in recognition ... fields of crafts, design, food and style. , ... the MSAMAs, which celebrates entrepreneurs and artisans who are ... and changing the way we shop, work and live,” ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the world’s ... to Chennai, India, tomorrow to speak at the Indian ... , Dr. Jivraj is founder of the Anacapa Dental ... one of the world’s foremost prosthodontists, meaning he is ... speaking to the Indian Society of Oral Implantologists about ...
Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
(Date:10/1/2014)... Finnland, October 1, 2014 ... Bereich der Biowissenschaften   Die Biowissenschaften ... und Gehen zahlreicher Detektionstechnologien. Einige davon sind ... Standard. Die Photonen-Upconversion ist eine neuartige Detektionstechnologie, ... mit Begeisterung aufgenommen wurde. Jetzt ist diese ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... of Health (NIH) awarded Lawrence Livermore National Laboratory ... array system that will enable researchers to better ... and scale. , LLNL,s grant-funded project is part ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... understanding of the human mind and uncover ways ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
Other Contents